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The ability of certain species of Chlamydia to inhibit the biogenesis of phagolysosomes permits their survival and replication
within macrophages. The survival of macrophage-adapted chlamydiae correlates with the multiplicity of infection (MOI), and
optimal chlamydial growth occurs in macrophages infected at anMOI of<1. In this study, we examined the replicative capacity
of Chlamydia muridarum in the RAW 264.7 murine macrophage cell line at different MOIs. C. muridarum productively infected
these macrophages at lowMOIs but yielded few viable elementary bodies (EBs) whenmacrophages were infected at a moderate
(10) or high (100) MOI.While highMOIs caused cytotoxicity and irreversible host cell death, macrophages infected at a moder-
ate MOI did not show signs of cytotoxicity until late in the infectious cycle. Inhibition of host protein synthesis rescued C. muri-
darum in macrophages infected at a moderate MOI, implying that chlamydial growth was blocked by activated defense mecha-
nisms. Conditionedmedium from these macrophages was antichlamydial and contained elevated levels of interleukin 1 (IL-
1), IL-6, IL-10, and beta interferon (IFN-). Macrophage activation depended on Toll-like receptor 2 (TLR2) signaling, and
cytokine production required live, transcriptionally active chlamydiae. A hydroxyl radical scavenger and inhibitors of inducible
nitric oxide synthase (iNOS) and cathepsin B also reversed chlamydial killing. High levels of reactive oxygen species (ROS) led to
an increase in cathepsin B activity, and pharmacological inhibition of ROS and cathepsin B reduced iNOS expression. Our data
demonstrate that MOI-dependent TLR2 activation of macrophages results in iNOS induction via a novel ROS- and cathepsin-
dependent mechanism to facilitate C. muridarum clearance.
Infection of host epithelial cells byChlamydia spp. sets inmotiona cascade of signaling events that recruit multiple innate im-
mune effectors to the infected site. Upon recognition of chlamyd-
ial pathogen-associated molecular patterns (PAMPs) and host
danger signals, infiltrating leukocytes undergo transcriptional re-
programming to amplify the immune response by producing sev-
eral cytokines and antimicrobial factors. The subsequent inflam-
matory process aids in bacterial clearance and primes elements of
adaptive immunity while also contributing to the damaging pa-
thology associated with chlamydial disease (1, 2).
Cells of themonocyte-macrophage lineage play critical roles in
innate and adaptive immunity against chlamydial infections. De-
pletion of macrophages from mice prior to infection with Chla-
mydia muridarum and Chlamydia psittaci results in increased
morbidity and pathogen burden (3, 4). Adoptive transfer of mac-
rophages to RAG-1//gamma interferon (IFN-)/ mice has
been shown to be sufficient for the control of Chlamydia pneu-
moniae in lung models of infection (5). Chlamydia trachomatis is
rapidly rerouted to lysosomes in RAW macrophages, where the
pathogen is killed (6).Macrophage killing and subsequent presen-
tation of elementary body (EB) antigens plays a key role in prim-
ing CD4 T-cell responses to chlamydial infection (7). However,
macrophage activities may not lead to immediate pathogen clear-
ance, since some species of Chlamydia can survive and undergo
limited replication in these cells. For instance, lymphogranuloma
venereum (LGV) biovar, but not oculogenital biovar, strains ofC.
trachomatis can productively infect macrophages (8–10).C. pneu-
moniae and C. psittaci have been similarly shown to replicate in
macrophages by preventing maturation of the phagosome (11,
12). Chlamydial persistence or replication within phagocytic cells
correlates with infection resolution and disease outcome. LGV
strains are highly invasive and cause systemic infections by dis-
semination through the lymphatic system (13). These strains also
require a longer antibiotic regimen for effective treatment than
non-LGV strains (14). Persistent infection of macrophages by C.
pneumoniae in several tissues has been associated with chronic
inflammatory conditions, including atherosclerosis, reactive ar-
thritis, and asthma (15, 16).
Intracellular replication of chlamydiae within macrophages in
vitro is less efficient than in epithelial cells and is limited by the
constitutive expression of perforin-2 in macrophages (17). Pro-
ductive infection also appears to be contingent upon the macro-
phage activation state and multiplicity of infection (MOI). Mac-
rophages classically activated by IFN- and lipopolysaccharide
(LPS) or other microbial PAMPs switch to an M1 polarized state.
This correlates with increased bacterial killing via proinflamma-
tory cytokines, production of reactive oxygen species (ROS) and
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upregulation of inducible nitric oxide synthase (iNOS) (18). Sev-
eral types of immune cells secrete IFN- in response to chlamydial
infection, likely favoring M1 polarization (19). M2 anti-inflam-
matorymacrophages are activated by interleukin 4 (IL-4) or IL-10
and participate in wound healing and fibrosis (18). None of the
evaluated chlamydial species survive in M1 macrophages in vitro,
but whether they selectively replicate in M2 or resting-macro-
phage (M0) reservoirs as opposed to M1 in vivo is unknown (20–
23). Interestingly, a virulent strain of C. psittaci, 6BC, recruits M0
instead of activated macrophages in mice, and this correlates with
increased morbidity (3). Other chlamydial species may also mod-
ulate the macrophage activation state or possess alternative mac-
rophage subversion strategies.
Early work with macrophages isolated from various hosts and
tissues indicated that recovery of chlamydial infectious particles is
also dictated by the MOI (8, 12, 24). Optimal recoveries were
obtained when macrophages were infected at an MOI of 1 or less.
MOIs on the order of 10 to 250 of C. psittaci and C. trachomatis
L2/434/Bu led to decreased EB recovery, and this was attributed to
host cell cytotoxicity occurring within the first 6 to 10 h of infec-
tion.
In this study, we examined chlamydial recoveries from cells of
the murine RAW 264.7 macrophage line (RAW macrophages)
infected with themouse pathogenC. muridarum atMOIs ranging
from 0.5 to 100. We observed a decrease in chlamydial survival
with increasing MOI, consistent with previous studies (12, 24).
Interestingly, amajority of cells infected at anMOI of 10 remained
healthy but failed to support chlamydial development. However,
these cells produced high levels of proinflammatory cytokines,
iNOS-derived nitric oxide (NO), and ROS, indicative of M1 po-
larization. Induction of iNOS expression depended on an increase
in cathepsin B activity and ROS accumulation. Blocking iNOS,
ROS, or cathepsin B restored chlamydial growth in moderately
infected macrophages. Together, our results indicate that a novel
ROS- and cathepsin B-dependent pathway for NO production
controls the growth of C. muridarum in RAW macrophages. Im-
portantly, our results also suggest that differing MOIs might ex-
plain some seemingly contradictory results concerning the rela-
tive importance of iNOS in the control of chlamydial infections
reported previously.
MATERIALS AND METHODS
Cell lines and chlamydial propagation. The murine RAW 264.7 macro-
phage line was a kind gift from Cheng Kao (Indiana University, Bloom-
ington, IN). RAW cells were maintained in low-adhesion 10-cm bacterial
petri dishes (VWR) in RPMI 1640medium containing 2mM L-glutamine
(Life Technologies) supplemented with 10% fetal bovine serum albumin
(FBS) (Atlanta Biologicals), 10 mM HEPES (Gibco), and 1 mM sodium
pyruvate. Only low-passage-number (4) macrophages were used for
experiments.C.muridarum (a generous gift fromHarlan Caldwell, Rocky
Mountain Laboratories, NIAID, NIH) (62) was propagated in McCoy
mouse fibroblasts (American Type Culture Collection CRL-1696), and
EBs were purified as previously described (25). The McCoy cells were
cultured inDulbecco’s modified Eagle’s medium (DMEM)–high-glucose
medium with 4 mM L-glutamine, 110 mg/liter sodium pyruvate (Hy-
Clone), 10% FBS, 10 mMHEPES, and 100 M nonessential amino acids
(Gibco).
Infection of RAW cells and inclusion-forming unit (IFU) assays.
RAW cells were seeded in 24-well cell culture plates (Thermo Scientific)
48 h prior to infection. Chlamydial infections were performed on conflu-
ent monolayers in sucrose-phosphate-glutamic acid (SPG) buffer by cen-
trifugation at 168 g at room temperature (RT) for 1 h. Following infec-
tion, the SPG buffer was replaced with fresh culture medium, and the
plateswere incubated at 37°C in 5%CO2. In some experiments, RAWcells
were treated 30 min prior to infection with one or more of the following
reagents: 1 mM L-NG-monomethyl arginine citrate (L-NMMA), 2 mM
L-NG-nitroargininemethyl ester (L-NAME) (Cayman Chemical), 15mM
N,N=-dimethylthiourea (DMTU) (Acros Organics), 50 or 100 ng/ml IL-
1Ra, 25 M acetyl (Ac)-YVAD-CHO (Peprotech), 25 M Z-WEHD-
FMK, and 25 M CA-074 Me (kind gifts of Stanley Spinola, Indiana
University School of Medicine, Indianapolis, IN). Treatment continued
throughout the course of infection. The infected monolayers were fro-
zen in 500l SPG buffer at 24 h postinfection (p.i.). Upon thawing, the
cells were scraped from the wells and agitated with 3-mm glass beads to
harvest EBs.
IFU assays were then performed by infecting McCoy cells in 96-well
plates (Thermo Fisher) with serial dilutions of the harvests of experimen-
tal infections. At 24 h p.i., the cells were fixed with methanol and stained
with mouse anti-chlamydial LPS monoclonal antibody (MAb) (EVIH1),
followed by a secondary Alexa Fluor 488-conjugatedMAb (Life Technol-
ogies). Chlamydial inclusions were imaged and counted using an Evos FL
Auto Cell Imaging System (Life Technologies).
Cytotoxicity assay. Lactate dehydrogenase (LDH) assays were per-
formed according to the manufacturer’s instructions (OPS Diagnostics).
RAW cells were infected with C. muridarum at an MOI of 0.5, 10, or 100.
Maximal LDH release was determined by treating cells in control wells
with 10% Triton X-100 10 min prior to the assay. Supernatants were
removed from the wells at the indicated time points after a brief spin to
remove debris. In a 96-well plate, 25 l of the supernatants was mixed
with 75l of the dye-buffer solution. Following incubation at 37°C for 15
min, absorbance was measured at 490 nm.
Immunofluorescence microscopy. RAW macrophages were grown
on glass coverslips in 24-well plates. The cells were infected by centrifu-
gation, fixed at 2 h p.i. with 4% formaldehyde, and permeabilized with
0.05% saponin. The cells were blocked in phosphate-buffered saline
(PBS) containing 0.1% bovine serum albumin (BSA) for 1 h, and then the
chlamydial inclusions were stained with the primary MAb EVIH1, fol-
lowed by an anti-mouse Alexa Fluor 488-conjugated secondary antibody
(Life Technologies). The coverslips were mounted on glass slides using
ProLong Gold antifade reagent with DAPI (4=,6-diamidino-2-phenylin-
dole) (Life Technologies), and images were captured using a Leica
DMI6000 B inverted microscope with a 63 oil immersion objective.
UV inactivation ofC.muridarum EBs. EB stocks were diluted in SPG
buffer at a 1:10 ratio, pipetted onto a petri dish, and exposed to 1,200
J/cm2 twice in a UV-cross-linking cabinet (Spectralinker; Spectronics
Corporation) (26, 27). The efficacy of theUV treatment was confirmed by
IFU assays.
Cytokine analysis.Culture supernatants were collected from infected
RAW macrophages at the indicated times and centrifuged briefly to re-
move debris. The supernatants were assayed for IL-1, IL-6, 1L-10, IL-
12p40, tumor necrosis factor alpha (TNF-), and IFN- (Milliplex) at the
Bio-Plex core (IUPUI, Indianapolis, IN) according to the manufacturer’s
instructions. IFN- levels were determined using amouse IFN- enzyme-
linked immunosorbent assay (ELISA) kit according to themanufacturer’s
instructions (BioLegend, San Diego, CA).
IFNAR1, TLR2, andTLR4neutralization experiments.RAWmacro-
phages were incubated for 1 h with antibody (10 to 30 g/ml) and then
stimulated with C. muridarum (MOI 	 10), conditioned medium, or
C. muridarum (MOI 	 0.5) with either 500 U/ml recombinant mouse
IFN- (R&D Systems) or 0.5 ng/ml E. coli LPS. Anti-IFNAR1 (clone
MAR1.5A3), anti-Toll-like receptor 4 (TLR4)-MD2 (cloneMTS510), an-
ti-TLR2 (clone T2.5), and isotype-matched IgG1 and IgG2A antibodies
were purchased from BioLegend (San Diego, CA). Cells were harvested
for IFU assays at 24 h p.i., and supernatants from anti-TLR2-treatedmac-
rophages were assayed for IFN- levels using an ELISA kit (BioLegend).
Griess assay. Nitrite concentrations in culture media were measured
with a commercial Griess assay kit (Biotium), and 150 l of culture su-
Cathepsin B and iNOS-Dependent Killing of C. muridarum
August 2015 Volume 83 Number 8 iai.asm.org 3165Infection and Immunity
pernatant was removed from infected monolayers at 6, 12, and 24 h p.i.
The samples were incubatedwith 20l Griess reagent [0.05%N-(1-naph-
thyl)ethylenediamine dihydrochloride, 0.5% sulfanilic acid, 2.5% phos-
phoric acid] in a 96-well plate at room temperature for 30 min. Absor-
bance was measured at 540 nm, and nitrite levels were calculated from a
sodium nitrite standard curve.
Western blot analysis. Infected RAW cells were treated with various
reagents; washed with PBS at 6, 12, or 24 h p.i.; and then incubated in 50
l lysis buffer (2% sodium dodecyl sulfate [SDS], 10% glycerol, 62 mM
Tris, pH 6.8) containing a protease inhibitor minitablet (Pierce) for 10
min on ice. The cell lysates were boiled for 5 min, and protein samples
were separated by SDS-PAGE and transferred to nitrocellulose mem-
branes. The membranes were incubated at 4°C overnight with rabbit
iNOS MAb or rabbit GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) MAb and then incubated for 1 h with a secondary anti-rabbit–
horseradish peroxidase conjugate. Antibodies were purchased from Cell
Signaling Technology (Danvers, MA). Proteins were visualized using
SuperSignal West Dura Chemiluminescent Substrate (Pierce) according
to the manufacturer’s instructions.
ROS assay. ROS production of infected RAW cells in 96-well clear-
bottom black plates (Corning) was assayed using the fluorogenic dye
2=,7=-dichlorofluorescein diacetate (DCFDA) (Abcam). Twenty micro-
molar DCFDA was mixed with culture media 45 min prior to measure-
ment of fluorescence intensity (excitation and emission wavelengths, 485
nm and 535 nm).
Cathepsin B activity assay.RAWmacrophages were cultured on cov-
erslips in 24-well plates. Infections and pharmacological treatments of
RAWmacrophages were performed. At 10 h p.i., reconstitutedMagic Red
cathepsin B substrate reagent MR-(RR)2 (Immunochemistry Technolo-
gies) was added directly to the culture media in the wells. After 30 min of
treatment, nuclei were counterstained with Hoechst 33342 for 10 min.
Coverslips were analyzed for cathepsin B activity by fluorescence micros-
copy (Leica DMI6000 B; 63 oil immersion objective). Fluorescence in-
tensities were quantified from 10 images obtained from each of three
independent experiments using ImageJ software (28).
Statistics. Data were analyzed using Prism 6.0 software (GraphPad).
For comparisons ofmultiple groupswith two ormore variables, data were
subjected to log transformation and two-way analysis of variance
(ANOVA)with Bonferroni posttest.Multiple comparisons for data with a
single variable were analyzed by one-way ANOVA with Dunnett’s post-
test. Differences in values between two groups were determined using
Student’s t test. Differences were considered statistically significant when
the P value was
0.05.
RESULTS
ProductiveC.muridarum infection of RAWmacrophages is de-
pendent on the multiplicity of infection. The effects of the MOI
on C. muridarum IFU production were examined in RAW mac-
rophages (Fig. 1A). At the lowest MOI (0.5), we observed a 2-fold
increase in IFU recovery over input, which is in agreement with
previous reports (24, 29). Maximal IFU recovery occurred when
macrophages were infected at an MOI of 1. IFU recovery de-
creased at MOIs of 3 and higher. At moderate (10) and high (100)
MOIs, IFU recoverieswere approximately 0.001%and 0.0001%of
input, respectively.
To determine if reduced IFU recovery at moderate and high
MOIs could be explained by host cell death, infectedmacrophages
were examined by lightmicroscopy (Fig. 1B toG). Cells infected at
a high MOI exhibited rounding and cytotoxicity (Fig. 1G). How-
ever, most cells infected at amoderateMOI had normalmorphol-
ogies (Fig. 1F) and released basal levels of LDH until late in the
chlamydial developmental cycle (see Fig. S1 in the supplemental
FIG 1 C.muridarum is inhibited in RAWmacrophages infected at a highMOI. (A)Macrophages were infected withC.muridarum atMOIs from 0.5 to 100. IFU
assays were performed at 24 h p.i. (B to G) Light microscopy of macrophages either mock infected (B) or infected with C. muridarum at various MOIs (0.5 [C],
3 [D], 5 [E], 10 [F], or 100 [G]) at 18 h p.i. (H) Numbers of inclusions counted per cell in macrophages infected at different MOIs at 2 h p.i. The error bars
represent standard deviations (SD).
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material). To test if low IFU recovery could be explained by re-
duced EB entry into macrophages, internalized EBs were quanti-
fied by fluorescence microscopy at 2 h p.i. The numbers of cyto-
solic EBs correlated with the input MOI (Fig. 1H). Overall, these
findings suggested that moderateMOI infection triggeredmacro-
phage activation to inhibit chlamydial EB production.
Chlamydial inhibition in RAW macrophages requires de
novo host protein synthesis. To elucidate the mechanism of C.
muridarum growth inhibition in RAW macrophages, we initially
tested if the antichlamydial factors were preformed. Infectedmac-
rophages were treated with cycloheximide to block protein syn-
thesis either 4 h prior to or at the time of infection. Cycloheximide
did not increase IFU production of macrophages infected at an
MOI of 100 (Fig. 2). In contrast, cycloheximide treatment prior to
and at the time of infection increased IFU production of macro-
phages infected at an MOI of 0.5 (low) by 3-fold and of macro-
phages infected at an MOI of 10 by more than 10,000-fold. These
results implied that at low and moderate MOIs, C. muridarum
inducedmacrophage defenses, whereas higherMOIs causedmac-
rophage death.
Supernatants from RAW macrophages contain heat-sensi-
tive antichlamydial factors. Activated macrophages release cyto-
kines that can stimulate neighboring cells (30), so we tested if
conditioned supernatants from infected macrophages could in-
hibit C. muridarum infection of newly infected macrophages.
Conditioned supernatants from RAW cells infected at low or
moderate MOIs were collected at various intervals postinfection.
The conditioned supernatants were then transferred onto macro-
phages that had just been infected with C. muridarum at an MOI
of 0.5 by centrifugation. Supernatants from low-MOI infections
failed to inhibit chlamydial growth (Fig. 3). In contrast, superna-
tants from moderate-MOI infections strongly inhibited IFU pro-
duction. The degree of this inhibition varied from 4-fold with 4-h
p.i. supernatants to 1,000-foldwith 24-h p.i. supernatants andwas
completely abolished if the supernatants were heated at 95°C
for 5 min.
Cytokine secretion from RAWmacrophages varies with the
C.muridarum EB dose and treatment.To attempt to identify the
trans-acting inhibitory factor(s), we assayed cytokines in the con-
ditioned supernatants of macrophages that had been infected at
variousMOIs. The levels ofmost of the cytokines produced by the
moderately infected macrophages peaked by 3 h p.i. and were
higher than those produced by the macrophages infected at low
levels (Fig. 4A). High levels of TNF-were detected at bothMOIs,
but the cytokine peaked earlier in supernatants from the macro-
phages infected at the higher MOI (Fig. 4A).
Since killed and viable EBs elicit dissimilar cytokine responses
(31, 32), cytokines in supernatants from macrophages that were
infected with nonreplicating chlamydiae at an MOI of 10 (wild-
type EBs with rifampin or UV-inactivated EBs) were assayed.
With the exception of TNF-, cytokine levels were substantially
lower than those observed in experiments with viable C. muri-
darum (Fig. 4B). Overall, the results of these experiments sug-
gested that most cytokine secretion required an antigen not pres-
ent in EBs and which was synthesized de novo by C. muridarum in
the host macrophage.
IFN- secreted by RAWmacrophages induces antichlamyd-
ial responses. IFN- has been previously shown to have an anti-
chlamydial role in macrophages (33), so we tested if IFN- se-
creted by moderately infected RAW macrophages stimulated
host defense pathways. IFN- signaling was blocked by treating
RAWmacrophages with an IFNAR1-neutralizing antibody (anti-
IFNAR1), and these macrophages were then treated with condi-
tioned medium from moderately infected macrophages. The
anti-IFNAR1 antibody, but not an isotype control, increased the
chlamydial yield 75-fold (Fig. 5A). Chlamydial inhibition medi-
ated by the addition of exogenous IFN- tomacrophages infected
at a low MOI was reversed by anti-IFNAR1, confirming the spec-
ificity of the antibody (Fig. 5B). Thus, our results indicated that
IFN- secretion in response to a moderate level of C. muridarum
infection contributed to the paracrine upregulation of antichla-
mydial macrophage defense mechanisms.
Antichlamydial activity ofRAWmacrophages ismediatedby
TLR2, but not TLR4.Chlamydial cell wall antigens and heat shock
proteins induce TLR2 and, to a lesser extent, TLR4 signaling
in phagocytes and epithelial cells (34, 35). To determine if TLR2 or
TLR4 activation stimulated macrophage antichlamydial re-
sponses, we used antibodies to specifically block TLR2 (anti-
FIG 2 Inhibition of host protein synthesis rescues chlamydial growth inmod-
erately infectedmacrophages. RAWmacrophages were treated with 0.5g/ml
cycloheximide 4 h before or at the time of infection at various MOIs. IFU
assays were performed at 24 h p.i. Black bars, untreated; white bars, cyclohex-
imide addition at 4 h prior to infection; gray bars, cycloheximide addition at 0
h p.i. ****, P
 0.0001; ***, P
 0.001; *, P
 0.05. Shown are means and SD.
FIG 3 Supernatants frommoderately infectedmacrophages contain antichla-
mydial factors. RAW macrophages were infected with C. muridarum at an
MOI of 0.5 or 10. Supernatants from these infections were removed at 4, 8, 12,
or 24 h p.i. and transferred ontomacrophages that had been freshly infected at
an MOI of 0.5. Some supernatants were heated at 95°C for 5 min prior to
transfer. IFU assays were performed on supernatant-treated macrophages at
24 h p.i. Black bars, mock treated; white bars,MOI	 0.5; horizontally hatched
bars, MOI 	 0.5 and heated; gray bars, MOI 	 10; obliquely hatched bars,
MOI	 10 andheated). ****,P
 0.0001; ***,P
 0.001; *,P
 0.05. Shown are
means and SD.
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TLR2) and TLR4 (anti-TLR4) responses. Control experiments
were performed to establish that both antibodies effectively
blocked cognate TLR function in RAW cells. Anti-TLR2 treat-
ment of moderately infected macrophages reduced IFN- pro-
duction in a dose-dependent manner (Fig. 6A). Anti-TLR4 abol-
ished chlamydial inhibition that was elicited by adding E. coli LPS
to RAW macrophages infected with C. muridarum at a low MOI
(Fig. 6B). However, only anti-TLR2 partially restored C. muri-
darum IFU production in macrophages infected at a moderate
MOI (Fig. 6C and D). This indicated that the antichlamydial re-
sponse of macrophages infected at moderate MOIs is primarily
mediated by TLR2.
FIG 4 Cytokine profiles of infected macrophages. (A) RAW macrophages were infected at an MOI of 0.5 (black bars) or 10 (gray bars). Supernatants were
collected at 3, 6, 12, 18, and 24 h p.i. and assayed for cytokines. (B) Supernatants were collected at 24 h p.i. from RAW cells infected at an MOI of 0.5 or 10 with
live EBs in the absence or presence of rifampin (RIF 10) or UV EBs (UV 10). ****, P
 0.0001. Shown are means and SD.
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Chlamydial inhibition at moderate MOIs is mediated by
iNOS and ROS. Macrophages activated by chlamydial infection
upregulate expression of iNOS, an enzyme that catalyzes NO for-
mation (29, 33, 36, 37). They can also accumulate high levels of
ROS via the phagocyte NADPH oxidase complex (phox) or dam-
aged mitochondria (38). To determine if iNOS was induced in
RAW macrophages by C. muridarum infection, we measured the
quantity of nitrites in culture supernatants. Higher nitrite levels
were observed in supernatants from macrophages infected at a
moderate MOI than from macrophages infected at a low MOI
(Fig. 7A). The levels of iNOS protein measured by Western blot-
ting correlated with supernatant nitrite levels (Fig. 7B). While
iNOS was not detected in cells infected at a low MOI, iNOS was
detected by 6 h p.i. in macrophages infected at a moderate MOI.
The macrophage ROS response was assessed by incubating in-
fected cells with the fluorogenicDCFDA.ROSproduction ofmac-
rophages infected at an MOI of 0.5 was low at all measured time
intervals (Fig. 7C). However, macrophages infected at a moderate
MOI produced strong fluorescence, which was almost entirely
reversed by the addition of the hydroxyl radical scavenger DMTU.
To evaluate the chlamydicidal potential of macrophage-de-
rived NO and ROS, infected macrophages were treated with the
iNOS inhibitors L-NMMA and L-NAME or the hydroxyl radical
scavenger DMTU. None of these compounds affected chlamydial
recovery in low-MOI infections (Fig. 7D). However, both iNOS
inhibitors and DMTU increased IFU production in the macro-
phages infected at a moderate MOI (39, 40). These results indi-
cated that moderately infected RAW macrophages stimulated
production of NO and reactive oxygen species that inhibited C.
muridarum.
Ca-074Me, a cathepsin B inhibitor, rescues C. muridarum
from antichlamydial macrophage responses. Many cytokines
can stimulate macrophage iNOS expression, including caspase-1-
dependent IL-1 (41–43). Since infected RAW macrophages se-
creted IL-1, we evaluated its role, as well as that of caspase-1, in
chlamydial inhibition using various inhibitors. Pretreatment of
FIG 5 Secreted IFN- inhibitsC.muridarum in RAWmacrophages. (A) IFU frommacrophages infectedwithC.muridarum at anMOI of 0.5 and incubatedwith
conditioned media from uninfected (mock) or moderately infected (MOI 	 10) cells. Some wells were pretreated with anti-IFNAR1 or isotype control IgG1
antibody (Ab) (10g/ml). (B) IFU frommacrophages infected withC.muridarum at anMOI of 0.5. Somewells treated with 500U/ml IFN-were preincubated
with anti-IFNAR1 or isotype control IgG1 Ab. ****, P
 0.0001; ***, P
 0.001; **, P
 0.01; *, P
 0.05. Shown are means and SD.
FIG 6 TLR2, but not TLR4, mediates macrophage inhibition ofC. muridarum at intermediateMOIs. (A)Macrophages pretreated with anti-TLR2 were infected
at an MOI of 0.5 (black bars) or 10 (gray bars). IFN- levels in supernatants at 24 h p.i. were measured by ELISA. (B) IFU from macrophages infected with C.
muridarum at an MOI of 0.5 at 24 h p.i. Some wells exposed to E. coli LPS were treated with anti-TLR4 or IgG2A isotype control Ab (10 g/ml). (C and D) IFU
at 24 h p.i. frommacrophages infected at anMOI of 10 treated with anti-TLR2 or IgG1 isotype control Ab (30g/ml) (C) and anti-TLR4 or IgG2A (D). ****, P

0.0001; ***, P
 0.001. Shown are means and SD.
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the macrophages with IL-1Ra, an IL-1 antagonist, did not influ-
ence chlamydial recovery (Fig. 8A). The caspase-1 inhibitor Ac-
YVAD-CHOalso failed to alter IFUproduction.However, the less
specific caspase-1 inhibitor Z-WEHD-FMK increased IFU recov-
ery in moderately infected macrophages approximately 10-fold.
Z-WEHD-FMK can also inhibit lysosomal cathepsins (44), so we
treated infectedmacrophages with the selective cathepsin B inhib-
itor Ca-074Me. Ca-074Me increased IFU production by 1,000-
fold in moderately infected macrophages (Fig. 8B). Analysis of
cathepsin B activity at 10 h p.i. using the fluorogenic substrate
CV-(RR)2 indicated no difference in fluorescence intensity be-
tweenmock-infected cells and cells infected at a lowMOI (Fig. 8C
and D; see Fig. S2 in the supplemental material). In contrast, ca-
thepsin B activity was significantly increased in the macrophages
infected at a moderateMOI, and this was reversed by the addition
of Ca-074Me (Fig. 8E and F; see Fig. S2 in the supplemental ma-
terial). Together, these results indicated that increased cathepsin B
activity in RAWmacrophages influences chlamydial IFU produc-
tion.
ROS and cathepsin B activities are necessary for maximal
iNOS induction in C. muridarum-infected RAWmacrophages.
Pharmacological inhibition of ROS, iNOS, and cathepsin B led to
similar chlamydial recoveries. We asked if these effector mecha-
nisms exerted additive effects, but combined inhibition did not
improve chlamydial recovery beyond that observed with single-
drug treatments (Fig. 9A). This suggested that they functioned in
the same inhibitory pathway or that they played cooperative roles
in chlamydial killing. To distinguish between these possibilities,
we first analyzed iNOS protein and nitrite levels in moderately
infected macrophages treated with L-NAME, DMTU, or Ca-
074Me. L-NAME interferes with iNOS activity, but not expres-
sion. Western blots showed equal quantities of iNOS protein in
untreated and L-NAME-treated cells, but nitrite levels were re-
duced in samples treated with L-NAME (Fig. 9B; see Fig. S3 in the
supplemental material). However, both iNOS and nitrite levels
were substantially lower in cells treatedwithDMTUorCa-074Me.
This indicated that ROS and cathepsin B controlled iNOS expres-
sion.
We next investigated if ROSmodulated cathepsin B activity or
vice versa. Addition of DMTU tomacrophages infected at a mod-
erateMOI decreased cathepsin B activity to levels lower than those
inmock-infected cells (Fig. 9C to E; see Fig. S4 in the supplemental
material). Conversely, inhibition of cathepsin BwithCa-074Me in
similarly infected macrophages caused a similar and small de-
crease in DCFDA fluorescence (see Fig. S5 in the supplemental
material). However, since NO production was also inhibited in
macrophages treated with Ca-074Me, we reasoned that the slight
reduction in DCFDA intensity might be due to an absence of
peroxynitrite. Indeed, DCFDA fluorescence levels did not differ
between Ca-074Me- and L-NAME-treated macrophages (see Fig.
S5 in the supplemental material). In summary, these results sug-
gested that ROS production increased cathepsin B activity, which
upregulated iNOS expression.
DISCUSSION
Members of the family Chlamydiaceae differ in their capacities to
survive within macrophages, and this correlates with their ability
to avoid fusion with lysosomes inside these cells (12). The ability
to survive and replicate in macrophages has been linked to in-
creased dissemination of C. trachomatis LGV strains, leading to
systemic disease (13). Chlamydial persistence inmacrophages can
result in chronic inflammation and a delayed response to antibi-
otic treatment (14, 45). Thus, understanding themechanisms that
FIG 7 Moderately infected RAWmacrophages inhibit C. muridarum by producing nitric oxide and reactive oxygen species. (A) Supernatants and protein were
collected at 6, 12, or 24 h p.i. from RAW cells infected at an MOI of 0.5 (black bars) or 10 (gray bars). Nitrite levels were quantified by Griess assay. (B) Western
blotting for iNOS levels. (C) RAW cells infected at an MOI of 0.5 (black bars), 10 (gray bars), or 10 with DMTU (white bars) were assayed for ROS production
at 1, 3, 6, 12, 18, and 24 h p.i. (D) RAW cells infected at anMOI of 0.5 or 10 were left untreated (black bars) or were treated with L-NMMA (white bars), L-NAME
(gray bars), or DMTU (hatched bars). IFU assays were performed 24 h p.i. ****, P
 0.0001; **, P
 0.01; *, P
 0.05. Shown are means and SD.
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promote chlamydial survival in mononuclear phagocytes could
have implications for the development of therapeutic strategies.
Chlamydial species that can evade phagolysosomal fusion
within macrophages appear to do so only when host cells are in-
fected at an optimal MOI. Several groups have reported reduced
chlamydial recoveries frommacrophages infected at MOIs of 100
or greater (12, 24). This correlated with immediate damage to the
host cells and fusion of lysosomes with EB-containing phago-
somes. In this study, we characterized the interactions of RAW
264.7 macrophages with C. muridarum and demonstrated that
three different outcomes could be achieved in response to differ-
ent MOIs. At an MOI of 1 or lower, RAW cells supported chla-
FIG 8 Ca-074Me, a cathepsin B inhibitor, rescuesC.muridarum frommacrophage inhibition. (A) RAWmacrophages were infected at anMOI of 0.5 (black bar)
or 10 (gray bar). Some cells infected at an MOI of 10 were treated with IL-1Ra at 50 g/ml (white bar) or 100 g/ml (crosshatched bar), Ac-YVAD-CHO
(horizontally hatched bar), or Z-WEHD-FMK (obliquely hatched bar). (B) Treatment of macrophages infected at an MOI of 10 with CA-074Me. Shown are
means and SD. (C to F) Representative live-microscopy images of cells at 10 h p.i. treated with the cathepsin B indicator dye MR-(RR)2 (red channel) and the
nuclear stain Hoechst 33342 (blue channel). (C)Mock infected. (D)MOI	 0.5. (E)MOI	 10. (F)MOI	 10 with Ca-074Me. ****, P
 0.0001; ***, P
 0.001.
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mydial replication. AnMOI of 100 conferred immediate cytotox-
icity, and few infectious chlamydial particles were recovered.
Inhibition of host protein synthesis did not prevent chlamydial or
host cell death. However, when RAWmacrophages were infected
at an intermediateMOI of 10, they did not succumb to early death
and cleared C. muridarum infection by a process that could be
reversed by cycloheximide.
Consistent with previous studies, we found that macrophage
activation and subsequent clearance of C. muridarum were pre-
dominantly mediated by TLR2 (46, 47). The cognate chlamydial
ligands for TLR2 have not been identified, but several candidates
have been proposed in recent years. Recombinant chlamydial
MIP-like protein can induce cytokine production via TLR2/
TLR1/TLR6 and CD14 in human macrophages (48). Chlamydial
LPS is less active than classic endotoxins but can elicit TLR2 sig-
naling in vitro (49). Chlamydial Hsp60 induces inflammatory re-
sponses in mice in a TLR2- and TLR4-dependent fashion (34).
Plasmid-deficient strains of C. trachomatis and C. muridarum ex-
hibit impaired TLR2 responses, implying that one or more TLR2
antigens are either encoded or regulated by the plasmid (50, 51).
Cytokine production via TLR2 signaling in epithelial cells also
requires infection with live, replicating chlamydiae, indicating
that the antigen is not present in EBs (32). Culture supernatants of
RAWmacrophages infected at an MOI of 10 were inhibitory and
contained elevated levels of several cytokines, including IFN-,
which induced a paracrine antichlamydial pathway. Cytokine se-
cretion by RAW cells required TLR2, as well as transcriptionally
active chlamydiae.
FIG 9 iNOS expression inmoderately infectedmacrophages is regulated by ROS and cathepsin B. (A) RAWmacrophages infected at anMOI of 10 were treated
with one of more of the following chemicals: L-NAME, DMTU, and Ca-074Me. Shown are means and SD. (B) Western blot for iNOS at 24 h p.i. from
mock-infected cells (lane 1); cells infected at anMOI of 0.5 (lane 2), 10 (lane 3), or 10 with L-NAME (lane 4); cells infected at anMOI of 10 with DMTU (lane 5);
and cells infected at an MOI of 10 with Ca-074Me (lane 6). (C to E) Representative live-microscopy images of cells at 10 h p.i. treated with the cathepsin B
indicator dyeMR-(RR)2 (red channel) and the nuclear stainHoechst 33342 (blue channel). (C)Mock infected. (D)MOI	 10. (E)MOI	 10 withDMTU. ****,
P
 0.0001.
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Binding ofmicrobial PAMPs toTLRs or other cytosolic pattern
recognition receptors (PRRs) triggers cellular signaling events that
culminate in the activation of NF-B, mitogen-activated protein
kinase (MAPK) or IRF3 pathways (52, 53). These in turn regulate
the expression of genes that encode proinflammatory cytokines
and iNOS. Aside from the direct induction of iNOS by PRR sig-
naling, several cytokines can also regulate iNOS expression. Pro-
tective effects of nitric oxide in chlamydial infections have been
well documented. Nitric oxide promotes IFN--mediated eradi-
cation of chlamydiae and protects mice from the development of
hydrosalpinx and infertility (54). Interestingly, TLR2/TLR4 dou-
ble-deficient mice do not resolve C. pneumoniae lung infections
because they do not induce iNOS, in spite of elevated IFN- se-
cretion in these animals (55). This suggests that nitric oxide pro-
duction relies on signaling via TLR2/TLR4 in the murine lung
model of infection.We observed that RAWmacrophages infected
with C. muridarum at an MOI of 10 produced more iNOS and
nitrite than cells infected an MOI of 0.5 and that this negatively
impacted chlamydial survival. Our results are reminiscent of a
study byHuang et al. in which the outcomes of low and high doses
of intranasally inoculated chlamydiae in C57BL/6 mice were eval-
uated (56). Animals infected with higher numbers of C. psittaci
remained healthier than those that were infected at low doses, and
the accelerated bacterial clearance in heavily infected mice was
linked to an increased NO production by macrophages. Compa-
rable observations have been reported with C. muridarum infec-
tions of themurine genital tract, where high infectious doses result
in less disease severity and fewer viable organisms in the oviducts
(57). We speculate that similar macrophage activation programs
control NO production in response to higher doses of infectious
chlamydiae in both mice and cell culture.
We determined that iNOS induction in RAW macrophages
was mediated by an increase in ROS production. Modulation of
iNOS expression by ROS is not without precedent. High-MOI
infection of macrophages with Propionibacterium acnes increases
ROS levels, which in turn upregulate iNOS via NF-B/AP-1 acti-
vation (58). Similar dependence on ROS for nitric oxide produc-
tion has also been observed in mouse endothelial cells stimulated
with IFN- and LPS (59). Multiple ROS sources exist within
mammalian cells, including the NADPH oxidase complex and
mitochondria. Whether ROS generated by RAWmacrophages in
our studywasmitochondrion orNADPHoxidase derivedwas not
determined. Several groups have reported a loss of mitochondrial
membrane potential and integrity in cells invaded by pathogens
(60). The subsequent mitochondrial ROS release can cause lyso-
somal membrane permeabilization (LMP), leading to the leakage
of active lysosomal cathepsins into the cytosol. In agreement with
these studies, we noted increased cathepsin B activity in RAWcells
that was abolished by an ROS scavenger. However, a significant
proportion of this cathepsin B activity at 10 h p.i. appeared to
localize to large vesicular structures. Labeling with specific mark-
ers will be required to determine if these vesicles are lysosomes or
also include EB-containing phagosomes that fused with lyso-
somes. Whether lysosomal cathepsin B leaks into the cytosol at
later times due to ROS-mediated LMP requires further investiga-
tion. What is certain is that ROS affects cathepsin B activity in
RAWmacrophages. Surprisingly, the inhibition of cathepsin B led
to a substantial decrease in iNOS and nitrite levels while also en-
abling chlamydial rescue. Pharmacological inhibition of iNOS
did not greatly affect ROS levels or cathepsin B (unpublished
observations) (see Fig. S5 in the supplemental material), indi-
cating that chlamydial survival in RAW cells was dictated by the
presence or absence of NO. However, we cannot rule out a
direct role for ROS and cathepsin B in chlamydial inhibition,
because chlamydiae damaged by reactive oxygen and nitrogen
species might become more susceptible to lysosomal fusion
and processing by cathepsin B.
Cathepsin B andROS act in concert as innate immune effectors
to activate NLRP3 inflammasome complexes, leading to IL-1
production (61). Inflammasome-derived IL-1 can stimulate
iNOS-mediated nitric oxide production in macrophages to in-
hibit Leishmania spp. (42). Blocking IL-1 signaling inRAWmac-
rophages did not reverse chlamydial killing or affect iNOS and
nitrite levels (Fig. 8A and unpublished observations), so precisely
how ROS and cathepsin B regulate iNOS expression in these cells
remains unclear. A protective role for cathepsin B in immunity to
C. muridarum disease in mice has not been described, and thus,
future experiments will involve confirming our observations in
primary macrophages and determining C. muridarum infection
outcome in cathepsin B/mice.
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